XERS vs. KYMR, MOR, CRNX, ALVO, IMVT, CPRX, HCM, OGN, AMRX, and MIRM
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Organon & Co. (OGN), AMNEAL PHARMACEUTICALS (AMRX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.
Xeris Biopharma vs. Its Competitors
Kymera Therapeutics (NASDAQ:KYMR) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.
Xeris Biopharma has higher revenue and earnings than Kymera Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kymera Therapeutics had 8 more articles in the media than Xeris Biopharma. MarketBeat recorded 8 mentions for Kymera Therapeutics and 0 mentions for Xeris Biopharma. Kymera Therapeutics' average media sentiment score of 0.60 beat Xeris Biopharma's score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media.
Xeris Biopharma has a net margin of -20.25% compared to Kymera Therapeutics' net margin of -409.07%. Xeris Biopharma's return on equity of 0.00% beat Kymera Therapeutics' return on equity.
Kymera Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Kymera Therapeutics currently has a consensus target price of $59.11, suggesting a potential upside of 36.11%. Xeris Biopharma has a consensus target price of $6.25, suggesting a potential upside of 31.03%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kymera Therapeutics is more favorable than Xeris Biopharma.
42.8% of Xeris Biopharma shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Kymera Therapeutics beats Xeris Biopharma on 10 of the 17 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:XERS) was last updated on 7/9/2025 by MarketBeat.com Staff
Free XERS Stock Alerts